Cite
MLA Citation
Richard E Clark et al.. “De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial.” Lancet, vol. 6, no. 7, 2019, pp. e375–e383. http://access.bl.uk/ark:/81055/vdc_100086499865.0x000009